AKUMS

Akums Drugs & Pharmaceuticals Share Price

 

 

Akums Drugs & Pharmaceuticals live price: ₹504.9. It opened at ₹496 vs previous close ₹490; intraday high/low: ₹515/₹495. The 50 & 200 DMA stand at ₹473.51/₹490.29.

Akums Drugs & Pharmaceuticals Performance

  • Today's Low
  • ₹495
  • Today's High
  • ₹515
  • 52 Week Low
  • ₹409
  • 52 Week High
  • ₹623
  • Open Price₹496
  • Previous Close₹490
  • Volume210,859
  • 50 DMA₹473.51
  • 100 DMA₹467.54
  • 200 DMA₹490.29

Investment Returns

  • Over 1 Month + 6.44%
  • Over 3 Month + 13%
  • Over 6 Month + 14.62%
  • Over 1 Year + 13.18%

Smart Investing Starts Here Start SIP with Akums Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Akums Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 7,947
  • P/B Ratio
  • 2.5
  • Average True Range
  • 19.47
  • EPS
  • 20.62
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.45
  • RSI
  • 57.96
  • MFI
  • 53.03

Akums Drugs & Pharmaceuticals Financials

Akums Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹504.90
+ 15.35 (3.14%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹484.44
  • 50 Day
  • ₹473.51
  • 100 Day
  • ₹467.54
  • 200 Day
  • ₹490.29

Resistance and Support

504.97 Pivot Speed
  • R3 534.93
  • R2 524.97
  • R1 514.93
  • S1 494.93
  • S2 484.97
  • S3 474.93

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Akums Drugs & Pharmaceuticals Ltd. is India’s leading contract manufacturing company, producing a wide range of pharmaceutical and nutraceutical products. It provides end-to-end solutions, including formulation development, manufacturing, and packaging for domestic and global clients.

Akums Drugs And Pharmaceuticals Ltd has an operating revenue of Rs. 4,256.70 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 8% is okay, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its key moving averages, around 4% and 3% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 21% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 21 which is a POOR score indicating inconsistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 89 indicates it belongs to a poor industry group of Medical-Products and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Akums Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
2025-05-26 Audited Results
2025-02-06 Quarterly Results

Akums Drugs & Pharmaceuticals F&O

Akums Drugs & Pharmaceuticals Shareholding Pattern

75.26%
10.95%
0.6%
1.38%
5.34%
6.47%

Akums Drugs & Pharmaceuticals FAQs

Akums Drugs & Pharmaceuticals share price is ₹504 As on 09 April, 2026 | 07:28

The Market Cap of Akums Drugs & Pharmaceuticals is ₹7946.8 Cr As on 09 April, 2026 | 07:28

The P/E ratio of Akums Drugs & Pharmaceuticals is 25 As on 09 April, 2026 | 07:28

The PB ratio of Akums Drugs & Pharmaceuticals is 2.5 As on 09 April, 2026 | 07:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23